Search
Congress Materials
XIFAXAN®
(rifaximin) 550 mg tablets
IBS-D
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference—September 7–9, 2023, National Harbor, MD
Comparative pharmacokinetics of rifaximin 550 mg and 200 mg oral tablets: one is not like the other
Heimanson Z, et al.
American Neurogastroenterology and Motility Society (ANMS) Annual Scientific Meeting—August 11–13, 2023, Austin, TX
Treatment-free interval (TFI): a novel approach to assessing real-world treatment response among patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline
Lacy BE, et al.
Association between symptoms in irritable bowel syndrome with diarrhea (IBS-D): a pooled correlation and tricomposite endpoint analysis of two phase 3, randomized, placebo-controlled, rifaximin trials
Staller K, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2022—October 21–26, 2022, Charlotte, NC
Rifaximin improves both fecal urgency and stool consistency in adults with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two randomized, phase 3 trials
Cash BD, et al.
The strong association between bloating, abdominal pain, and global irritable bowel syndrome (IBS) symptom scores in IBS with diarrhea: a phase 3 trial pooled correlation analysis of individual symptoms
Staller K, et al.
AAFP FMX 2022—September 20–23, 2022, Washington, DC
A new trisymptom composite endpoint to evaluate the efficacy of rifaximin for multiple symptoms of irritable bowel syndrome with diarrhea: a pooled analysis of two randomized, phase 3 trials [Encore]
Lacy BE, et al.
Society of General Internal Medicine (SGIM) 2022 Annual Meeting—April 6–9, 2022, Orlando, FL
Rifaximin improves both abdominal pain and bloating in patients with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two phase 3, randomized, placebo-controlled trials [Encore]
Lacy BE, et al.
Digestive Disease Week (DDW) 2021—May 21–23, 2021, Virtual
Rifaximin improves both abdominal pain and bloating in patients with irritable bowel syndrome with diarrhea: a composite endpoint analysis of two phase 3, randomized, placebo-controlled trials
Lacy BE, et al.
Rifaximin significantly improves bowel movement urgency in patients with irritable bowel syndrome with diarrhea: a pooled analysis of three phase 3 trials
Schoenfeld PS, et al.
AAFP FMX 2020—October 13–17, 2020, Virtual
Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications [Encore]
Rao SSC, et al.
United European Gastroenterology (UEG) Week 2020—October 11–13, 2020, Virtual
Efficacy of rifaximin on bloating in patients with diarrhea‐predominant irritable bowel syndrome (IBS-D): a pooled analysis of three phase 3, randomized, placebo‐controlled trials
Lacy B, et al.
Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea in adults previously treated with other IBS medications [Encore]
Rao SSC, et al.
American Association of Nurse Practitioners (AANP) National Conference 2020—September 10, 2020–December 31, 2020, Virtual
Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications [Encore]
Kassebaum A, et al.
Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual
Pooled analysis of two phase 3, placebo-controlled studies assessing the impact of colonoscopy timing on rifaximin efficacy in irritable bowel syndrome with diarrhea (IBS-D)
Chang C, et al.
Rifaximin is efficacious for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults previously treated with other IBS medications
Rao SSC, et al.
AAFP FMX 2019—September 24–28, 2019, Philadelphia, PA
Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]
Lacy BE, et al.
American Neurogastroenterology and Motility Society 2019 Annual Meeting—August 16–18, 2019, Chicago, IL
Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]
Lacy BE, et al.
Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline (BL) pain severity [Encore]
Lembo A, et al.
American Association of Nurse Practitioners (AANP) National Conference 2019—June 18–23, 2019, Indianapolis, IN
Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity [Encore]
Allen C, et al.
Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]
Lorenzen S, et al.
Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA
Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response [Encore]
Lacy BE, et al.
Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity [Encore]
Lembo A, et al.
AAFP FMX 2018—October 9–13, 2018, New Orleans, LA
Rifaximin for irritable bowel syndrome-related bloating
Lacy BE, et al.
Rifaximin for abdominal pain in irritable bowel syndrome with diarrhea
Lembo A, et al.
Impact of prior irritable bowel syndrome medication use on rifaximin
Lembo A, et al.
Rifaximin safety profile in irritable bowel syndrome [Encore]
Weinstock LB, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2018—October 5–10, 2018, Philadelphia, PA
Rifaximin for improving abdominal pain and bloating symptoms in patients with irritable bowel syndrome with diarrhea (IBS-D) using modified definitions of pain response
Lacy BE, et al.
Characterization of abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea (IBS-D), by baseline pain severity
Lembo A, et al.
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference 2018—September 7–9, 2018, Las Vegas, NV
Characterization of abdominal pain response in patients with irritable bowel syndrome with diarrhea treated with rifaximin [Encore]
Faiman O, et al.
Efficacy of rifaximin on bloating in patients with irritable bowel syndrome with diarrhea: a pooled analysis of three phase 3, randomized, placebo-controlled trials [Encore]
Lacy BE, et al.
American Association of Nurse Practitioners (AANP) National Conference 2018—June 26–July 1, 2018, Denver, CO
Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome (IBS) treated with rifaximin [Encore]
Lembo A, et al.
Digestive Disease Week (DDW) 2018—June 2–5, 2018, Washington, DC
Efficacy of rifaximin on bloating in patients with diarrhea‐predominant irritable bowel syndrome (IBS‐D): a pooled analysis of three phase 3, randomized, placebo‐controlled trials
Lacy BE, et al.
Efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and prior use of IBS medications
Lembo AJ, et al.
Rifaximin repeat treatment for diarrhea-predominant irritable bowel syndrome (IBS-D) and impact on Clostridium difficile infection development
Pimentel M, et al.
Lack of development of opportunistic infections, including candidiasis, in patients with diarrhea-predominant irritable bowel syndrome receiving repeat treatment with rifaximin
Pimentel M, et al.
Characterization of long-term rifaximin responders from a phase 3, randomized, double-blind, placebo-controlled repeat treatment trial for diarrhea-predominant irritable bowel syndrome (IBS-D)
Weinstock LB, et al.
American Academy of Pain Medicine (AAPM) 34th Annual Meeting—April 25–29, 2018, Vancouver, Canada
Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with rifaximin [Encore]
Lembo A, et al.
World Congress of Gastroenterology (WCG) at ACG 2017—October 13–18, 2017, Orlando, FL
Responders analysis in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with rifaximin
Lembo AJ, et al.
Assessing the efficacy of rifaximin in diarrhea-predominant irritable syndrome (IBS-D): a post hoc analysis of two phase 3, randomized, placebo-controlled trials
Pimentel M, et al.
American Association of Nurse Practitioners (AANP) National Conference 2017—June 20–25, 2017, Philadelphia, PA
Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials [Encore]
Lembo A, et al.
American Academy of Physician Assistants (AAPA) Conference 2017—May 15–19, 2017, Las Vegas, NV
Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials [Encore]
Landers M, et al.
Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL
Impact of rifaximin on health-related quality of life in patients with diarrhea-predominant irritable bowel syndrome
Cash BD, et al.
Characterization of abdominal pain response in patients with diarrhea-predominant irritable bowel syndrome treated with rifaximin
Lembo AJ, et al.
Sustained response and predictors of sustained response in patients who respond to multiple courses of rifaximin for diarrhea-predominant irritable bowel syndrome
Pimentel M, et al.
Society of General Internal Medicine (SGIM) 2017 Annual Meeting—April 19–22, 2017, Washington, DC
Assessment of the safety and tolerability of the antibiotic rifaximin for irritable bowel syndrome (IBS): a pooled analysis of three phase 3 studies [control ID #2699361]
Chang C, et al.
Third Annual Translational Microbiome Conference—April 11–13, 2017, Boston, MA
Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhea-predominant irritable bowel syndrome
Fodor A, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2016—October 14–19, 2016, Las Vegas, NV
Analysis of potential predictors of symptom recurrence in patients treated with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D)
Lembo AJ, et al.
Safety and tolerability of rifaximin in the treatment of irritable bowel syndrome (IBS): a pooled analysis of 4 randomized, placebo-controlled trials
Lembo AJ, et al.
Improvements over time in individual diarrhea-predominant irritable bowel syndrome symptoms (IBS-D) with rifaximin repeat treatment
Pimentel M, et al.
Efficacy of rifaximin on bowel movement urgency in patients with diarrhea-predominant irritable bowel syndrome (IBS-D): a pooled analysis of 3 phase 3 trials
Pimentel M, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2015—October 16–21, 2015, Honolulu, HI
Infection-related safety profile of rifaximin repeat treatment for diarrhea-predominant irritable bowel syndrome (IBS-D)
Chey WD, et al.
Antibiotic susceptibility of skin swab Staphylococcus isolates from patients with diarrhea-predominant irritable bowel syndrome (IBS-D) treated with repeat courses of rifaximin show no evidence of resistance
Schoenfeld P, et al.
Digestive Disease Week (DDW) 2015—May 17–19, 2015, Washington, DC
Improvements in IBS-related quality of life in a randomized, controlled repeat treatment trial (TARGET 3) of rifaximin for IBS-D
Cash BD, et al.
Comparison of symptoms, health care utilization, and treatment in diagnosed and undiagnosed patients with IBS with diarrhea
Chang L, et al.
Characterizing the effect of rifaximin on individual symptoms of IBS-D: findings from the open-label phase of TARGET 3
Chang L, et al.
Enduring effects following a course of rifaximin therapy in patients with IBS-D: incremental benefit upon repeat treatment
Lacy BE, et al.
Safety and tolerability of rifaximin in a repeat treatment study in subjects with IBS-D: results from TARGET 3 [Encore]
Lembo A, et al.
Durability of benefit in IBS-D patients responding to a 2-week course of rifaximin: results from TARGET 3
Pimentel M, et al.
Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study
Pimentel M, et al.
Rifaximin for IBS-D: consistent treatment effect across demographic and baseline disease characteristics
Schoenfeld P, et al.
Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2015—April 7–10, 2015, San Diego, CA
Treatment patterns for Xifaxan (rifaximin) in patients with irritable bowel syndrome: a healthcare claims analysis [abstract K6 ; page S57]
Kirkwold JL, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2014—October 17–22, 2014, Philadelphia, PA
Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS-D): results of the TARGET 3 study
Lembo A, et al.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)